Ozmosi | AKTX-101 Drug Profile
Contact Us
Drug Profile
Using advanced filters...
Advanced Search [+]

AKTX-101

Alternative Names: AKTX-101, AKTX101, AKTX 101
Clinical Status: Active
Latest Update: 2026-04-21
Latest Update Note: News Article

Product Description

Akari Therapeutics, Plc (NASDAQ: AKTX) is an innovative targeted oncology company built on next generation antibody-drug conjugates (ADC) and a novel discovery engine. (Sourced from: https://akaritx.com/company-overview/)

Mechanisms of Action: TROP2 Inhibitor

Novel Mechanism: No

Modality: Antibody Drug Conjugate

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: AKARI
Company Location: Eastern America
Company Founding Year: 2013
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

  • Clinical Trial Start Expected - AKARI announced they will initiate a P1 Oncology Solid Tumor Unspecified|Pancreatic Cancer|Lung Cancer|Colorectal Cancer trial in 3Q27 for AKTX-101
  • Clinical Trial Start Expected - AKARI announced they will initiate a P1 Oncology Solid Tumor Unspecified trial in 3Q27 for AKTX-101
  • Clinical Outcomes Reported - AKARI presented P0 Pancreatic Cancer results on 2026-05-21 for AKTX-101

Highest Development Phases

Phase 0: Oncology Solid Tumor Unspecified

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

Recent News Events

Date

Type

Title

04/21/2026

News Article

 Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors

04/09/2026

News Article

 Akari Therapeutics Participates in Virtual Investor "What This Means" Interview Discussing Strategic Partnership with WuXi XDC

04/06/2026

News Article

 Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing

03/18/2026

News Article

 Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions